文献速递心律失常心力衰竭与心肌病

后壁隔离在持续性房颤合并收缩性心衰导管消融中的作用:一项随机临床试验的二次分析

The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该研究为CAPLA试验的二次分析,纳入98例持续性房颤合并症状性射血分数降低心衰(HFrEF)患者,比较肺静脉隔离(PVI)联合后壁隔离(PWI)与单纯PVI的疗效。结论提示PVI联合PWI并未改善心律失常复发或LVEF恢复,不支持在首次消融中常规加用PWI。

要点

  • PVI联合PWI与单纯PVI在12个月无AAD下无房性心律失常复发率无差异。
  • 两种消融策略均显著改善LVEF,但组间无差异。
  • 不推荐对持续性房颤合并HFrEF患者首次消融常规加用PWI。

核心结论

  • 在持续性房颤合并症状性HFrEF患者中,PVI联合PWI较单纯PVI未改善无心律失常复发率或LVEF恢复。
  • 导管消融可显著改善收缩功能,与消融策略无关。
  • 结果提示不应在HFrEF患者首次持续性房颤消融中常规加用PWI。

研究设计与样本

  • CAPLA试验的ad hoc二次分析,多中心、前瞻性、随机对照试验,涉及3个国家11个中心。
  • CAPLA试验纳入338例持续性房颤患者,随机接受PVI联合PWI或单纯PVI。
  • 本亚组纳入原CAPLA研究中伴有症状性HFrEF(LVEF<50%且NYHA≥II级)的患者,共98例。

临床怎么用

  • 对于持续性房颤合并HFrEF患者,首次导管消融不应常规加用后壁隔离。
  • 导管消融可显著改善此类患者的左室收缩功能。

局限性

  • 本研究为CAPLA试验的事后二次分析,样本量较小(98例),可能影响统计效能。
  • 结果需在更大规模的前瞻性研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Catheter ablation for patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) is associated with improved left ventricular ejection fraction (LVEF) and survival compared with medical therapy. Nonrandomized studies have reported improved success with posterior wall isolation (PWI). OBJECTIVE: To determine the impact of pulmonary vein isolation (PVI) with PWI vs PVI alone on outcomes in patients with HFrEF. DESIGN, SETTING, AND PARTICIPANTS: This was an ad hoc secondary analysis of the CAPLA trial, a multicenter, prospective, randomized control trial that involved 11 centers in 3 countries (Australia, Canada, and UK). CAPLA featured 338 patients with persistent AF randomized to either PVI plusPWI or PVI alone. This substudy included patients in the original CAPLA study who had symptomatic HFrEF (LVEF <50% and New York Heart Association class ≥II). INTERVENTIONS: Pulmonary vein isolation with PWI vs PVI alone. MAIN OUTCOMES AND MEASURES: The primary end point was freedom from any documented atrial arrhythmia greater than 30 seconds, after a single ablation procedure, without the use of antiarrhythmic drug (AAD) therapy at 12 months. RESULTS: A total of 98 patients with persistent AF and symptomatic HFrEF were identified (mean [SD] age, 62.1 [9.8] years; 79.5% men; and mean [SD] LVEF at baseline, 34.6% [7.9%]). After 12 months, 58.7% of patients with PVI plus PWI were free from recurrent atrial arrhythmia without the use of AAD therapy vs 61.5% with PVI alone (hazard ratio, 1.02; 95% CI, 0.54-1.91; P = .96). There were no significant differences in freedom from atrial arrhythmia with or without AAD therapy after multiple procedures (PVI plus PWI vs PVI alone, 60.9% vs 65.4%; P = .73) or AF burden (median, 0% in both groups; P = .78). Mean LVEF improved substantially in PVI plus PWI (∆ LVEF, 19.3% [13.0%; P < .01) and PVI alone (18.2% [14.1%; P < .01), with no difference between groups (P = .71). Normalization of LV function occurred in 65.2% of patients in the PVI plus PWI group and 50.0% of patients with PVI alone (P = .13). CONCLUSIONS AND RELEVANCE: The results of this study indicate that addition of PWI to PVI did not improve freedom from arrhythmia recurrence or recovery of LVEF in patients with persistent AF and symptomatic HFrEF. Catheter ablation was associated with significant improvements in systolic function, irrespective of ablation strategy used. These results caution against the routine inclusion of PWI in patients with HFrEF undergoing first-time catheter ablation for persistent AF. TRIAL REGISTRATION: http://anzctr.org.au Identifier: ACTRN12616001436460.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. William, Chieng, Sugumar, et al. The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37755920. doi:10.1001/jamacardio.2023.3208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。